Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lorlatinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT07671560
What this trial is testing

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Who this might be right for
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Qiming Wang 80
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Not applicableStudy completedNCT04979988
What this trial is testing

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Who this might be right for
ALK-positive Non-small-cell Lung Cancer
Pfizer 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT06007937
What this trial is testing

Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Who this might be right for
Non Small Cell Lung CancerMetastaticRecurrent
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)UnknownNCT03439215
What this trial is testing

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 20
Not applicableApproved For MarketingNCT03127618
What this trial is testing

Lorlatinib - PF-06463922

Pfizer
Early research (Phase 1)Study completedNCT04541407
What this trial is testing

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Who this might be right for
Non Small Cell Lung CancerCNS Progression
University of Colorado, Denver 1
Early research (Phase 1)Study completedNCT02564562
What this trial is testing

Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Who this might be right for
Healthy
Pfizer 6
Testing effectiveness (Phase 2)Study completedNCT03505554
What this trial is testing

Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
University of Milano Bicocca 9
Not applicableNot Yet RecruitingNCT06690541
What this trial is testing

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

Who this might be right for
Lung Cancer, Non-Small Cell
Peking University Cancer Hospital & Institute 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750704
What this trial is testing

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 153
Not applicableStudy completedNCT05167500
What this trial is testing

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Fundación GECP 118
Large-scale testing (Phase 3)Active Not RecruitingNCT03052608
What this trial is testing

Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 296
Not applicableNot Yet RecruitingNCT06904547
What this trial is testing

Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC

Who this might be right for
ALK-Positive NSCLC
Shanghai Chest Hospital 100
Very early researchLooking for participantsNCT06333899
What this trial is testing

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Who this might be right for
High Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma+6 more
Nationwide Children's Hospital 15
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Early research (Phase 1)Looking for participantsNCT07784959
What this trial is testing

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Who this might be right for
ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more
Nuvectis Pharma, Inc. 54
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Not applicableEnrolling By InvitationNCT06876675
What this trial is testing

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerHyperlipidemia
Peking University Third Hospital 167
Early research (Phase 1)Study completedNCT02804399
What this trial is testing

Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Who this might be right for
Healthy
Pfizer 12
Next Page